Eli Lilly’s weight loss pill shows success in Phase 3 trial
Ed Milner | Last update: 1st September 2025
There’s fresh momentum behind the much-anticipated oral weight loss pill, orforglipron. Following on from our report in August (read here) Eli Lilly has now confirmed the third successful Phase 3 trial and many expect the drug to shake up the obesity treatment market.
TL;DR
- Orforglipron is Eli Lilly’s oral GLP-1 weight loss drug
- A third major trial has shown strong results in people without diabetes
- Patients lost an average of 12% of body weight in 36 weeks
- If approved, it could offer a needle-free alternative to jabs like Mounjaro and Wegovy
- SlimrChat says: This could be big, but it’s still not approved in the UK
What’s new?
Eli Lilly has just announced results from a third successful Phase 3 trial of orforglipron, its daily pill alternative to injectable GLP-1 drugs like Mounjaro and Wegovy.
The trial focused on adults with obesity who do not have diabetes, and showed that participants on orforglipron lost up to 12% of their body weight after 36 weeks.
🔗 Read Eli Lilly’s announcement
What makes orforglipron different?
Unlike current weight loss drugs that require a weekly injection, orforglipron is a daily pill. This makes it far more convenient for people who are put off by needles or who struggle with injections.
Financial analysts say orforglipron could seriously shake up the $150 billion global weight loss market, especially if it receives fast-track approval in the US and Europe.
What’s next?
Eli Lilly plans to submit the drug for regulatory approval in 2026, meaning it could reach markets like the US and UK by late 2026 or 2027. Until then, injectables like Mounjaro and Wegovy remain the gold standard.
SlimrChat’s view
We know many in our community would welcome a needle-free option, and this news is promising. But it’s important to remember orforglipron is still not available, and the current wave of weight loss success stories is driven by injectables.
We’ll keep following orforglipron’s progress, and share updates as soon as there’s more news.